Rituximab for HIV-associated lymphoma: Weighing the benefits and risks

Michele Spina, Umberto Tirelli

Research output: Contribution to journalArticlepeer-review


Purpose of review: This review discusses the potential benefits and risks of using the anti-CD20 monoclonal antibody rituximab for the treatment of HIV-associated B-cell non-Hodgkin's lymphoma. Recent findings: Studies have consistently demonstrated that rituximab improves response and survival when combined with standard chemotherapy compared with chemotherapy alone in immunocompetent patients with intermediate-grade non-Hodgkin's lymphoma. Several recently reported phase II and III trials have evaluated the use of rituximab plus chemotherapy for HIV-associated B-cell non-Hodgkin's lymphoma. Phase II trials combining rituximab with either standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy or infusional chemotherapy have reported encouraging results, suggesting a similar benefit in HIV-positive individuals. A phase III trial comparing CHOP with CHOP-plus rituximab (R-CHOP) demonstrated a lower risk from progression of the lymphoma, but a higher risk of early and late infectious-related death in patients with a low CD4 count (

Original languageEnglish
Pages (from-to)462-465
Number of pages4
JournalCurrent Opinion in Oncology
Issue number5
Publication statusPublished - Sep 2005


  • HIV infection
  • Non-Hodgkin's lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Rituximab for HIV-associated lymphoma: Weighing the benefits and risks'. Together they form a unique fingerprint.

Cite this